These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 26952037)
1. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Lambert J; Wyand M; Lassen C; Shneyer L; Thomson E; Knight A; Willers J; Kay J Int J Clin Pharmacol Ther; 2016 Apr; 54(4):315-22. PubMed ID: 26952037 [TBL] [Abstract][Full Text] [Related]
2. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects. Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771 [TBL] [Abstract][Full Text] [Related]
3. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects. Zhang T; Chen G; Liu C; Zu L; Wang Q; Wang Y; Lv J; An Y; Dong L; Cheng H; Ren S; Wang Q; Zheng Q; Song H; Fang Y BioDrugs; 2019 Feb; 33(1):93-100. PubMed ID: 30511316 [TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects. Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Park W; Lee SJ; Yun J; Yoo DH Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834 [TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01). Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. Park KR; Chung H; Yang SM; Lee S; Yoon SH; Cho JY; Jang IJ; Yu KS Expert Opin Investig Drugs; 2017 May; 26(5):619-624. PubMed ID: 28290731 [TBL] [Abstract][Full Text] [Related]
9. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901 [TBL] [Abstract][Full Text] [Related]
12. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422 [TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Lee Y; Rho YH Ann Rheum Dis; 2018 Feb; 77(2):234-240. PubMed ID: 29042358 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. Singh I; Patel R; Patel A; Jose V Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects. Chow V; Oh M; Gessner MA; Fanjiang G Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783 [TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind, Parallel Controlled, Single-Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects. Zhou R; Chen Q; Hou S; Guo H; Li J; Qian W; Wang H; Ou L; Chen X; Jiang F; Jia J Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1028-1035. PubMed ID: 35778977 [TBL] [Abstract][Full Text] [Related]
17. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761 [TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]